非小细胞肺癌新辅助靶向治疗研究进展
Advances in Neoadjuvant Targeted Therapy for Non-small Cell Lung Can-cer
孙任成 1孙赛赛 1于渊2
作者信息
- 1. 潍坊市中医院肿瘤外科,山东潍坊 261041
- 2. 潍坊市人民医院肿瘤内科,山东潍坊 261041
- 折叠
摘要
随着靶向治疗为驱动基因阳性的晚期非小细胞肺癌(Non-small Cell Lung Cancer,NSCLC)以及术后辅助治疗的患者获益,肺癌靶向治疗的新辅助策略逐渐受到关注.近年来,NSCLC的新辅助靶向治疗临床试验研究数据不断更新,NSCLC新辅助靶向治疗安全有效,可增加根治性手术机会、减少疾病复发并改善患者预后.本文对驱动基因阳性的NSCLC应用新辅助靶向治疗的相关研究进行综述,以提高临床医生对新辅助靶向治疗的认识.
Abstract
With the benefit of targeted therapy for patients with advanced non-small cell lung cancer(NSCLC)with positive driver genes and postoperative adjuvant therapy,neoadjuvant strategies of targeted therapy for lung cancer are increasingly attracting attention.In recent years,the data of clinical trials of neoadjuvant targeted therapy in NSCLC have been constantly updated.Neoadjuvant targeted therapy in NSCLC is safe and effective,which can increase the chance of radical surgery,reduce disease recurrence and improve patient prognosis.This article reviews the relevant studies on the application of neoadjuvant targeted therapy in driver gene-positive NSCLC,in order to improve clini-cians'understanding of neoadjuvant targeted therapy.
关键词
非小细胞肺癌/新辅助靶向治疗/综述Key words
Non-small cell lung cancer/Neoadjuvant targeted therapy/Review引用本文复制引用
出版年
2024
NETL
NSTL
维普
万方数据